Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Assistant settings

journal：Clinical Cancer Research

Authors：Stephanie L. Wethington; Payal D. Shah; Lainie Martin; Janos L. Tanyi; Nawar Latif; Mark Morgan; Drew A. Torigian; Diego Rodriguez; Simon A. Smith; Emma Dean; Susan M. Domchek; Ronny Drapkin; Ie-Ming Shih; Eric J. Brown; Wei-Ting Hwang; Deborah K. Armstrong; Stephanie Gaillard; Robert Giuntoli; Fiona Simpkins

Published date：2023-8-1

DOI：10.1158/1078-0432.ccr-22-2444

PDF link：https://aacrjournals.org/clincan ... 422/ccr-22-2444.pdf

Article link：http://dx.doi.org/10.1158/1078-0432.ccr-22-2444

Article Source：American Association for Cancer Research (AACR)。


Remark：

This post has been completed

Completed attachments will be deleted within 24 hours.